Li Jifeng, Zeng Yifei, Wang Mengjie, Liu Yongxin, Guo Yubo, Zhao Wenjie, Huang Qiao, Zhang Dongxiao
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, People's Republic of China.
J Inflamm Res. 2024 Nov 11;17:8647-8657. doi: 10.2147/JIR.S492464. eCollection 2024.
Granulomatous lobular mastitis (GLM) has seen a rising incidence, though its pathogenesis remains unclear, posing challenges for treatment and contributing to high recurrence rates with conventional therapies. While the role of inflammatory and immune factors in GLM has been recognized, a comprehensive clinical evaluation of these markers is still lacking. This study aims to identify potential diagnostic markers and therapeutic targets by comparing immune markers and cytokine levels in GLM patients and healthy controls.
Conducted at Beijing Hospital of Traditional Chinese Medicine, Capital Medical University from July 2023 to May 2024, this study enrolled 30 GLM patients and 15 healthy female controls in a 2:1 ratio. Serum levels of immune markers and cytokines were analyzed to explore their potential association with GLM.
The study population comprised 30 GLM patients with a mean age of 33.40 ± 4.12 years and 15 healthy female controls with a mean age of 32.13 ± 6.19 years. Significantly elevated levels of C-reactive protein (CRP), Immunoglobulin A (IgA), Complement Component 3 (C3), Complement Component 4 (C4), Compliment Component 1q (C1q), Alpha1-antit-rypsin (AAT), α1-acidglycoprotein (AGP), Anti-histone antibodies (Anti-HIS), Anti-Ro52 antibodies (Anti-Ro52), Anti-double stranded DNA antibodies (Anti-dsDNA), Interleukin-6 (IL-6), Interleukin-10 (IL-10), and Tumor Necrosis Factor-α (TNF-α) were observed in GLM patients compared to controls (all P < 0.05). Subgroup analysis revealed higher levels of CRP, C3, C1q, AAT, and AGP in patients with larger mass areas and those with erythema nodosum (all P < 0.05). No significant differences were found in subgroups based on disease duration or recurrence (both P > 0.05).
Serum levels of CRP, IgA, AAT, AGP, Anti-HIS, Anti-Ro52, Anti-dsDNA, C3, C4, C1q, IL-6, IL-10, and TNF-α may serve as diagnostic and prognostic indicators for GLM, with CRP, AAT, AGP, and C1q being particularly indicative of disease severity. These markers offer potential therapeutic targets for GLM.
肉芽肿性小叶性乳腺炎（GLM）的发病率呈上升趋势，但其发病机制仍不清楚，这给治疗带来了挑战，且传统疗法的复发率较高。虽然炎症和免疫因子在GLM中的作用已得到认可，但对这些标志物仍缺乏全面的临床评估。本研究旨在通过比较GLM患者和健康对照者的免疫标志物和细胞因子水平，确定潜在的诊断标志物和治疗靶点。
本研究于2023年7月至2024年5月在首都医科大学附属北京中医医院进行，按照2:1的比例纳入30例GLM患者和15名健康女性对照。分析血清免疫标志物和细胞因子水平，以探讨它们与GLM的潜在关联。
研究人群包括30例GLM患者，平均年龄33.40±4.12岁，以及15名健康女性对照，平均年龄32.13±6.19岁。与对照组相比，GLM患者的C反应蛋白（CRP）、免疫球蛋白A（IgA）、补体成分3（C3）、补体成分4（C4）、补体成分1q（C1q）、α1-抗胰蛋白酶（AAT）、α1-酸性糖蛋白（AGP）、抗组蛋白抗体（Anti-HIS）、抗Ro52抗体（Anti-Ro52）、抗双链DNA抗体（Anti-dsDNA）、白细胞介素-6（IL-6）、白细胞介素-10（IL-10）和肿瘤坏死因子-α（TNF-α）水平显著升高（均P<0.05）。亚组分析显示，肿块面积较大和有结节性红斑的患者CRP、C3、C1q、AAT和AGP水平较高（均P<0.05）。基于病程或复发情况的亚组间未发现显著差异（均P>0.05）。
血清CRP、IgA、AAT、AGP、Anti-HIS、Anti-Ro52、Anti-dsDNA、C3、C4、C1q、IL-6、IL-10和TNF-α水平可能作为GLM的诊断和预后指标，其中CRP、AAT、AGP和C1q特别能反映疾病严重程度。这些标志物为GLM提供了潜在的治疗靶点。
